

(CH₂)₃OCH₂(CH₂OCH₂)₂(CH₂)₂NH₂, 4246-51-9; H₂N(CH₂)₃N-(Me)(CH₂)₃NH₂, 105-83-9; H₂NCH₂C₆H₄-*p*-CH₂NH₂, 539-48-0; BrCH₂C₆H₄-*p*-CH₂NH₂, 623-24-5; 4-(2-hydroxyethyl)-9-methylene-1,7-dioxo-4-azacyclododecane, 140605-27-2.

Supplementary Material Available: ¹H NMR spectra for *N,N'*-ditrityl-4,8-dithia-1,11-undecanediamine, 1-(5-hexenyl)-

1,2-bis(3-cyanoethoxy)ethane, 1,10-diamino-5-(5-hexenyl)-4,7-dioxadecane, 4-(2-hydroxyethyl)-9-methylene-1,7-dioxo-4-azacyclododecane, and 18, ¹³C NMR spectrum for 18, experimental details for the X-ray data, a comparison of the conformations of the 18-membered rings of 1, 2, and [2.2.2], and 10 tables of X-ray data for 1 and 2 (22 pages). Ordering information is given on any current masthead page.

Synthesis of Hydrindan Derivatives Related to Vitamin D¹

Benito Fernández, José A. Martínez Pérez, Juan R. Granja, Luis Castedo, and Antonio Mouriño*

Departamento de Química Orgánica, Facultad de Química y Sección de Alcaloides del CSIC, Universidad de Santiago de Compostela, 15706 Santiago de Compostela, Spain



Received December 12, 1991

Two independent routes to the CD fragment of vitamin D metabolites and analogues are described. The *trans*-hydrindanol 4 was synthesized from enedione 5. The key step in this synthesis was the hydroxyl-directed hydrogenation of hydrindenols of type 15 in the presence of Wilkinson's catalyst. The *trans*-hydrindanone 6 was efficiently prepared by degradation of the Lythgoe-Inhoffen diol (3). Both 4 and 6 are suitable precursors for the preparation of new potentially useful analogues of 1 α ,25-dihydroxyvitamin D₃ that are functionalized at C₂₀, C₂₁, or ring D.

Introduction

1 α ,25-Dihydroxyvitamin D₃ [1a, 1 α ,25-(OH)₂-D₃, calcitriol] (Chart I), the hormonally active form of vitamin D₃ (1b), in addition to controlling intestinal calcium absorption and bone calcium mobilization,² is also involved in cell differentiation and proliferation processes.³ The fact that this hormone cannot be used for the treatment of certain cancers due to its potent calcemic effects⁴ has led to interest in the synthesis of structurally modified analogues of 1 α ,25-(OH)₂-D₃ with potent effects on cell differentiation and proliferation without causing hypercalcemia.⁵ To date, a number of side-chain-modified analogues of 1 α ,25-(OH)₂-D₃ have been subjected to preliminary clinical studies with promising results.⁶

Among the various routes now available for the synthesis of vitamin D metabolites and analogues, those based on



the convergent coupling of the upper fragment (bicycle CD and side chain) to the bottom fragment (ring A) are particularly attractive.⁷ In these syntheses the CD and side-chain fragments are usually prepared from the Lythgoe-Inhoffen diol (3), which is obtained by degradation

(1) A short account of this work was partially presented at the 7th workshop on vitamin D: *Vitamin D. Molecular, Cellular and Clinical Endocrinology*; Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; Herrath, D. V., Eds.; Walter de Gruyter: Berlin, New York, 1988; p 34. This work was taken in part from the PhD thesis of B. Fernández.

(2) (a) Norman, A. W. *Vitamin D, The Calcium Homeostatic Steroid Hormone*; Academic Press: New York, 1979. (b) DeLuca, H. F.; Paaren, H. E.; Schnoes, H. K. *Top. Curr. Chem.* 1979, 83, 1. (c) Dickson, I. *Nature* 1987, 325, 18. (d) Jones, G. *Steroids* 1987, 49, 1. (e) DeLuca, H. F.; Burmester, J.; Darwish, H.; Krisinger, J. *Comprehensive Medicinal Chemistry*; Pergamon Press: New York, 1990; Vol. 3, p 1129.


(3) (a) Provedini, D. M.; Tsoukas, C. D.; Deftos, L. J.; Manolagas, S. C. *Science (Washington, D.C.)* 1983, 121, 1181. (b) Tsoukas, C. D.; Provedini, D. M.; Manolagas, S. C. *Ibid.* 1984, 224, 1438. (c) For review, see: Ostrem, V. K.; DeLuca, H. F. *Steroids* 1987, 49, 73.

(4) Koeffler, H. P.; Hirji, K.; Itri, L. *Cancer Treat. Rep.* 1985, 69, 1399.

(5) Figadère, B.; Norman, A. W.; Henry, H. L.; Koeffler, H. P.; Zhou, J.-Y.; Okamura, W. H. *J. Med. Chem.* 1991, 34, 2452 and references cited therein.

(6) (a) Wovkulich, P. M.; Batcho, A. D.; Baggiolini, E. G.; Boris, A.; Truitt, G.; Uskokovic, M. R. *Vitamin D, Chemical, Biochemical and Clinical Update*; Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; Herrath, D. V. Eds.; Walter de Gruyter: Berlin, 1985; p 755. (b) Abe, J.; Morikawa, M.; Miyamoto, K.; Kaiho, S.; Fukushima, M.; Miyaura, C.; Abe, E.; Suda, T.; Nishii, Y. *FEBS Lett.* 1987, 226, 58. (c) Calverley, M. J. *Tetrahedron* 1987, 43, 4609. (d) Zhou, J. Y.; Norman, A. W.; Collins, E.; Lubbert, M.; Uskokovic, M. R.; Koeffler, H. P. *Blood* 1989, 74, 82. (e) Binderup, E. *Drugs Future* 1990, 15, 15.

(7) (a) Okamura, W. H. *Acc. Chem. Res.* 1983, 16, 81. (b) Pardo, R.; Santelli, M. *Bull. Soc. Chim. Fr.* 1985, 98. (c) Vitamin D Active Compounds. Quinkert, G., Ed. *Synform* 1985, 1986, 1987, 3, 4, 5. (d) Castedo, L.; Mouriño, A.; Sarandeses, L. A. *Tetrahedron Lett.* 1986, 27, 1523. (e) Castedo, L.; Mascareñas, J. L.; Mouriño, A.; Sarandeses, L. A. *Tetrahedron Lett.* 1988, 29, 1203.



of vitamin D₂ (2). However, this prevents functionalization of other positions such as C₂₀, C₂₁, or ring D. As suitable precursors of new potentially useful vitamin D analogues functionalized at these positions, we have synthesized the *trans*-hydrindanol 4⁸ and the enedione 5⁹ and the *trans*-hydrindanone 6 by degradation of the Lythgoe–Inhoffen diol (3) (Scheme I).

Total Synthesis of Hydrindanol 4 (Scheme II). The commercially available enedione 5 was reduced under Luche's conditions¹⁰ to a mixture of alcohols 7a and 7b in quantitative yield. These alcohols, which can be separated by column chromatography (7a, 93%; 7b, 7%), were treated with acetic anhydride under standard conditions to give the mixture of diacetates 8 in 97% yield. The acetates 8 were treated with lithium in ammonia–diethyl ether to give the alcohol 9a (72%) and 7a,b (21%). Protection of the alcohol 9a with *tert*-butyldimethylsilyl chloride afforded 9b (100%).¹¹ The next stage of the

(8) For other syntheses of *trans*-fused hydrindans related to 4 starting from 5, see: (a) Baggiolini, E. G.; Iacobelli, J. A.; Hennessy, B. M.; Uskokovic, M. R. *J. Am. Chem. Soc.* 1982, 104, 2945. (b) Wovkulich, P. M.; Barcelos, F.; Batcho, A. D.; Sereno, J. F.; Baggiolini, E. G.; Hennessy, B. M.; Uskokovic, M. R. *Tetrahedron* 1984, 40, 2283. (c) Baggiolini, E. G.; Iacobelli, J. A.; Hennessy, B. M.; Batcho, A. D.; Sereno, J. F.; Uskokovic, M. R. *J. Org. Chem.* 1986, 51, 3098. (d) Daniewski, A. R.; Kiegiel, J. *J. Org. Chem.* 1988, 53, 5534. Daniewski, A. R.; Kiegiel, J. *Synth. Commun.* 1988, 18, 115. For other syntheses of *trans*-fused CD ring system in optically pure form, see: (e) Micheli, R. A.; Hajos, Z. G.; Cohen, N.; Parrish, D. R.; Portland, L. A.; Sciamana, W.; Scott, M. A.; Wehrli, P. A. *J. Org. Chem.* 1975, 40, 675. (f) Lythgoe, B.; Roberts, D. A.; Waterhouse, I. *J. Chem. Soc., Perkin Trans. 1* 1977, 2608. (g) Grieco, P. A.; Takigawa, T.; Moore, D. R. *J. Am. Chem. Soc.* 1979, 101, 4380. (h) Desmaele, D.; Ficini, J.; Guingant, A.; Touzin, A. M. *Tetrahedron Lett.* 1983, 24, 3083. (i) Haynes, R. K.; Vonwiller, S. C.; Hambley, T. W. *J. Org. Chem.* 1989, 54, 5162. (j) Yamada, H.; Shimizu, K.; Nisar, M.; Takahashi, T.; Tsuji, J. *Tetrahedron Lett.* 1990, 31, 2407.

(9) Enedione 5 (Aldrich) can be easily synthesized from 2-methyl-1,3-cyclopentadiene: Hajos, Z. G.; Parrish, D. R. *Org. Synth.* 1984, 63, 26. See also ref 8e.

(10) Luche, J. L. *J. Am. Chem. Soc.* 1978, 100, 2226.

Table I. Hydrogenation of 15



15a, R₁=TBS, R₂=H
 15b, R₁=TBS, R₂=AC
 15c, R₁=TBS, R₂=MOM
 15d, R₁=*t*-BuPh₂Si, R₂=H

starting compd	catalyst	solvent	cis:trans ratio	yield (%)
15a	Crabtree	CH ₂ Cl ₂	100:0	92
15a	Wilkinson	PhH	25:75	87
15b	Crabtree	CH ₂ Cl ₂	100:0	78
15b	Wilkinson	PhH	0:0	15b
15c	Crabtree	CH ₂ Cl ₂	0:0	15c
15c	Wilkinson	PhH	0:0	15c
15d	Crabtree	CH ₂ Cl ₂	100:0	87
15d	Wilkinson	PhH	35:65	85

planned synthesis required conversion of 9b to the corresponding *trans*-hydrindanol 4. Unfortunately, hydroboration–oxidation of 9b under the usual conditions [(1) B₂H₆ or 9-BBN; (2) H₂O₂, NaOH] afforded the *cis*-hydrindanol 10 as the major product (90% yield). Hydroboration of this type of compounds therefore appears to take place, like hydrogenation,¹² from the more exposed β-face. In view of this result, we decided to attempt hydroxyl-directed hydrogenation of hydrindenols of type 15, which are similar to those successfully hydrogenated in this way by Okamura and co-workers¹³ for the introduction of the *trans*-hydrindane nucleus.

Oxidation of alcohol 10 with pyridinium dichromate¹⁴ and subsequent treatment of the ketone 11 with trimethylsilyl iodide (LiI, TMSI, CH₂Cl₂) in hexamethyldisilazane (HMDS)^{13,15} afforded the silyl enol ether 12 (97%, two steps). Treatment of 12 with phenylselenenyl chloride in diethyl ether gave a 1:2.5 mixture of the α- and β-seleno derivatives 13, which after purification by column chromatography were oxidized with *m*-chloroperbenzoic acid (*m*-CPBA) in dichloromethane to give the enone 14 in 70% yield (two steps).¹⁶ Reduction of the latter under Luche's conditions¹⁰ afforded the desired allyl alcohol 15a (92%).

We first attempted hydrogenation of hexahydrindanol 15a to obtain the *trans*-hydrindane system using Crabtree's iridium catalyst ([Ir(Cod)Py(PCy₃)₂PF₆)]¹⁷. The sole product, however, was the *cis*-hydrindanol 16 (97% yield). The *cis*-fusion was easily inferred from the ¹H NMR spectrum, which showed a singlet at δ 1.04 typical of the 7a-methyl group of the *cis*-hydrindane system, and from the recovery of ketone 11 by oxidation of the alcohol 16 (PDC, CH₂Cl₂, 98%). In view of this unexpected result we tried Wilkinson's catalyst¹⁸ instead of Crabtree's. Hydrogenation of 15a in the presence of 25 mol % of this catalyst

(11) Corey, E. J.; Venkateswarlu, A. *J. Am. Chem. Soc.* 1972, 94, 6190.

(12) Fieser, L. F.; Fieser, M., Eds. *Steroids*; Reinhold: New York, 1959; p 212.

(13) (a) Hoeger, C. A.; Okamura, W. H. *J. Am. Chem. Soc.* 1985, 107, 268. (b) Hoeger, C. A.; Johnston, A. D.; Okamura, W. H. *J. Am. Chem. Soc.* 1987, 109, 4690. See also ref 8b.


(14) Corey, E. J.; Schmidt, G. *Tetrahedron Lett.* 1979, 399.

(15) Miller, R. D.; McKean, D. R. *Synthesis* 1979, 730.

(16) (a) For a review of organoselenium reagents, see: Reich, H. J. *Acc. Chem. Res.* 1979, 12, 22. (b) Sharpless, K. B.; Lauer, R. F.; Teranishi, A. Y. *J. Am. Chem. Soc.* 1973, 95, 6137. (c) Reich, H. J.; Wollowitz, S.; Trend, J. E.; Chow, F.; Wendelborn, D. F. *J. Org. Chem.* 1978, 43, 1697.

(17) Crabtree, R. H.; Davis, M. W. *J. Org. Chem.* 1986, 51, 2655.

(18) Birch, A. J.; Williamson, D. H. *Org. React.* 1974, 24, 74.



afforded a 3:1 mixture of the desired *trans*-hydrindanol 4 (65% isolated yield) and the *cis* isomer 16, which were separated by flash chromatography. The structure of 4 was confirmed by oxidation to the *trans*-fused ketone 17 (PDC, CH_2Cl_2 , 98%), whose ^1H NMR spectrum showed a singlet corresponding to the 7a-methyl group at δ 0.70 (as against δ 1.04 for the *cis* compound 11). Encouraged by the stereoselectivity of this hydrogenation, we extended our study to the directing effect of various protecting groups, with the results listed in Table I.¹⁹ We concluded (a) that only hydrogenation in the presence of Wilkinson's catalyst with the unprotected C_4 hydroxyl as directing group gives the desired *trans*-hydrindanol and (b) that the protecting group of the C_1 hydroxyl group must determine the degree of molecular convexity and therefore the ease with which the catalyst can coordinate to the C_4 alcohol from the α -face.²⁰

Partial Synthesis of Hydrindanone 6 (Scheme III). The starting material for the partial synthesis of 6 was the tosylate 18a, which can easily be prepared in 78% yield from vitamin D_2 (2) (O_3 , MeOH - Py ; NaBH_4 /*p*- TsCl , Py).²¹ Protection of 18a (TBSCl, imidazole, $\text{DMF}/\text{CH}_2\text{Cl}_2$)¹¹ gave the known tosylate 18b in 83% yield.²² In an attempt to obtain the aldehyde 19 we used standard Kornblum conditions (10 equiv of NaHCO_3 , DMSO),²³ but under these conditions epimerization occurred at C_{20} .²⁴ With 1 equiv of dry NaHCO_3 , the aldehyde 19 was obtained in 85% yield without detection of its 20*R* epimer by ^1H NMR (which clearly distinguishes the aldehyde hydrogens of the

(19) The bulky *tert*-butyldiphenylsilyl protecting group was introduced with the idea of preventing complexation of the catalyst with the oxygen at C_1 . Compound 15d was obtained as above starting from 9a.


(20) Attempts to obtain 17 by treatment 13 with *n*- Bu_3SnH , Et_3B , toluene, -20°C , *n*- Bu_3SnH , AIBN, benzene, 60°C , or *n*- Bu_3SnH , *n*- $\text{Bu}_3\text{SnSn}-\text{Bu}_3$, *h\nu*, benzene, 0°C led to a 6:1 mixture of the ketones 11 and 17 as determined by ^1H NMR. For the preparation of *trans*-hydrindan system using *n*- Bu_3SnH , see: Satoh, S.; Sodeoka, M.; Sasai, H.; Shibasaki, M. *J. Org. Chem.* 1991, 56, 2278.

(21) (a) Leyes, G. A.; Okamura, W. H. *J. Am. Chem. Soc.* 1982, 104, 6099. (b) Sardina, F. J.; Mouriño, A.; Castedo, L. *J. Org. Chem.* 1986, 51, 1264.

(22) This compound was previously prepared from vitamin D_2 by an alternative route (27%, eight steps): Castedo, L.; Mascareñas, J. L.; Mouriño, A. *J. Org. Chem.* 1986, 51, 1269.

(23) Kornblum, N.; Jones, W. J.; Anderson, G. J. *J. Am. Chem. Soc.* 1959, 81, 4113.

(24) For a better understanding, steroidal numbering was used in this case. While this work was in progress, an alternative procedure for the preparation of aldehyde 19 was reported (35%, seven steps): Dauben, W. G.; Ollmann, R. R.; Funhoff, A. S.; Neidlein, R. *Tetrahedron Lett.* 1989, 30, 677.



two epimers). The aldehyde 19 was transformed into 20 in good yield (82%) via an α -hydroperoxy aldehyde by bubbling oxygen through a *tert*-butyl alcohol solution of the aldehyde in the presence of potassium *tert*-butoxide.²⁵

Compound 6 was prepared in a three-step sequence by Baeyer-Villiger oxidation of 20 (*m*-CPBA, CH_2Cl_2 , rt),²⁶ hydrolysis of the resulting acetate 21a to the alcohol 21b (NaOH , $\text{MeOH}-\text{H}_2\text{O}$, rt), and oxidation of 21b to ketone 6 (PDC, CH_2Cl_2) [61% yield from 20, 35% overall yield from the Lythgoe-Inhoffen diol (3)]. An attempt to obtain ketone 6 directly from compound 20 under Siddall conditions (O_2 , *t*- BuOH -THF, $0-5^\circ\text{C}$)²⁷ afforded only 35–55% yields.

Correlation between Alcohol 4 and Ketone 6. To further prove the structures of compounds 4 and 6 we proceeded to convert both into the diol 22 (Scheme IV). Oxidation of 4 with pyridinium dichromate in dichloromethane provided the ketone 17 (98%), which was reduced with sodium borohydride in methanol to give the β -alcohol 23 (84%) together with the α -alcohol 4 (15%). Compound 23 was then deprotected (HF, acetonitrile)²⁸ to afford the diol 22 in 81% yield. Sodium borohydride reduction of 6 provided the alcohol 21b (97%), and deprotection (HF, acetonitrile) afforded an 80% yield of a product with a ^1H NMR and ^{13}C spectra identical to those of the diol obtained from 4.

Experimental Section

General. All dry solvents were distilled under argon. Et_2O , THF, and benzene were distilled from sodium/benzophenone. CH_2Cl_2 and DMF were distilled from P_2O_5 and DMF was stored under type 4-Å molecular sieves. Pyridine was distilled from KOH and dioxane from sodium. DMSO was purified by standing overnight with chromatographic grade alumina and distillation from CaH_2 at low pressure and was stored under type 4-Å molecular sieves. *m*-CPBA was crystallized from CH_2Cl_2 .²⁹ All reactions were conducted under Ar unless otherwise stated. Boiling points and melting points (open capillary tubes) are uncorrected. Kugelrohr oven temperatures (ot) refer to the external air bath temperature. ^1H NMR and ^{13}C spectra were recorded at 250 and 62.83 MHz using CDCl_3 as solvent. Mass spectra were measured using electron impact at 70 eV. Catalytic hydrogenations were carried out with a PARR 3915 hydrogenator. Flash chromatography was performed by Still's method.³⁰ TLC was

(25) Sucrow, W. *Chem. Ber.* 1967, 100, 259.

(26) Alternative Baeyer-Villiger reagents (Oxone, magnesium monopropthalate in $\text{MeOH}/\text{H}_2\text{O}$, and magnesium monopropthalate in phase-transfer $\text{Bu}_4\text{N}^+\text{Br}^-$, $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$) gave lower yields.

(27) Siddall, J. B.; Baddeley, G. V.; Edwards, J. A. *Chem. Ind. (London)* 1966, 25.

(28) Newton, R. F.; Reynolds, D. P.; Finch, M. A. W.; Kelly, D. R.; Roberts, S. M. *Tetrahedron Lett.* 1979, 3981.

(29) Traylor, T. G.; Miksztal, A. R. *J. Am. Chem. Soc.* 1987, 109, 2770.

performed on plates of silica gel (2 × 5 cm, 0.2-mm thickness). Components were located by observation of the plates under UV light and/or by treating the plates with a phosphomolybdic acid reagent followed by heating. Concentrations were carried out in a rotary evaporator. Drying was carried out with anhydrous Na₂SO₄.

[1*S*-(1*α*,5*α*,7*α*- and 1*α*,5*β*,7*α*)]-2,3,5,6,7,7*a*-Hexahydro-1,5-dihydroxy-7*a*-methyl-1*H*-indene (7*a* and 7*b*). Ene-dione 5⁹ (15 g, 91.5 mmol) and CeCl₃·7H₂O (34 g, 91.2 mmol) were dissolved in absolute EtOH (100 mL). The solution was cooled to 0 °C, and NaBH₄ (7 g, 183 mmol) was slowly added. The mixture was stirred for 10 min at rt and quenched by dropwise addition of H₂O. The resulting mixture was continuously extracted with Et₂O for 24 h, and the extract was dried, filtered, and concentrated to give a mixture of 7*a* and 7*b* (15 g, 100%). A 5-g portion of this mixture was flash chromatographed (3 × 25 cm, 30% EtOAc/hexanes) to give 4.64 g of 7*a* (93%) and 0.3 g of 7*b* (7%). 7*a* (*R*_f 0.36, 60% EtOAc/hexanes): IR (CHCl₃) 3400 cm⁻¹; ¹H NMR δ 5.37 (1 H, m, H-4), 4.26 (1 H, m, H-5), 3.62 (1 H, dd, *J* = 10 and 7.8 Hz, H-1), 1.02 (3 H, s, Me-7*a*); MS *m/z* 168 (M⁺, 1), 150 (M⁺ - H₂O, 36), 135 (28), 109 (100). Anal. Calcd for C₁₀H₁₆O₂: C, 71.37; H, 9.60. Found: C, 71.19; H, 9.69. 7*b* (*R*_f 0.25, 60% EtOAc/hexanes): ¹H NMR δ 5.49 (1 H, m, H-4), 4.15 (1 H, m, H-5), 3.62 (1 H, dd, *J* = 10 and 7.8 Hz, H-1), 0.92 (3 H, s, Me-7*a*).

[1*S*-(1*α*,5*α*,7*α*- and 1*α*,5*β*,7*α*)]-2,3,5,6,7,7*a*-Hexahydro-1,5-bis(acetyloxy)-7*a*-methyl-1*H*-indene (8). A solution of the epimeric mixture of 7 (14 g, 83.3 mmol) in dry pyridine (40 mL) and acetic anhydride (10.5 mL, 110 mmol) was stirred at rt for 48 h. Water was added (100 mL), and the mixture was extracted with Et₂O (3 × 75 mL). The combined organic phases were successively washed with 10% HCl until no pyridine was present (2 × 20 mL) and then with aqueous saturated NaHCO₃ (2 × 20 mL) and water (20 mL). Drying, filtration, and concentration in vacuo afforded 21.5 g of a yellow tar which was distilled bulb-to-bulb to give 20.4 g of 8 (97%, at 120–130 °C/0.5 mm Hg; *R*_f 0.85, 40% EtOAc/hexanes): IR (film) 1740 cm⁻¹; ¹H NMR δ 5.36 (1 H, m, H-4), 5.25 (1 H, m, H-5), 4.63 (1 H, dd, *J* = 10 and 6.7 Hz, H-1), 2.06 and 2.07 (3 H, 2 s, MeCO), 1.08 and 1.04 (3 H, 2 s, Me-7*a*). Anal. Calcd for C₁₄H₂₀O₄: C, 66.63; H, 8.01. Found: C, 66.78; H, 8.21.

[1*S*-(1*α*,7*α*)]-2,3,5,6,7,7*a*-Hexahydro-7*a*-methyl-1*H*-indene-1-ol (9*a*). NH₃ (400 mL) was collected in a flame-dried three-necked round-bottomed flask, fitted with NH₃ and N₂ inlets and previously cooled to -78 °C. Lithium was added in portions (5.25 g, 750 mmol), and the mixture was stirred for 20 min. A solution of 8 (11 g, 43.65 mmol) in Et₂O (100 mL) was slowly added with a syringe. The dry ice-acetone bath was removed after 2 h. The reaction mixture was stirred for 1.5 h and quenched by slow addition of solid NH₄Cl until the blue color disappeared. Water was added (100 mL), and NH₃ was removed by stirring under a stream of N₂. The mixture was concentrated, and the residue was extracted with EtOAc (200 mL). This organic phase was washed with water (2 × 30 mL), dried, filtered, and concentrated to give a yellowish oil which was flash chromatographed (3 × 60 cm, 20–40% EtOAc/hexanes) to afford 9*a* (4.8 g, 72%; mp 95–7 °C; *R*_f 0.66, 30% EtOAc/hexanes) and 7 (1.55 g, 21%; *R*_f 0.18, 30% EtOAc/hexanes): IR (KBr) 3300 cm⁻¹; ¹H NMR δ 5.36 (1 H, d, *J* = 2.8 Hz, H-4), 3.64 (1 H, dd, *J* = 9.8 and 7.7 Hz, H-1), 2.46 and 2.13 (2 H, m, CH₂-5), 0.95 (3 H, s, Me-7*a*); ¹³C NMR δ 144.2, 119.4, 82.2, 42.8, 34.4, 29.3, 25.7, 25.0, 18.6, 16.6; MS *m/z* 152 (M⁺ - H₂O, 40), 137 (16), 134 (25), 108 (49), 93 (100); high-resolution MS calcd for C₁₀H₁₆O (C₁₀H₁₆O₂ - H₂O) 152.1201, found 152.1230. Anal. Calcd for C₁₀H₁₆O₂: C, 78.88; H, 10.61. Found: C, 78.66; H, 10.50.

[1*S*-(1*α*,7*α*)]-2,3,5,6,7,7*a*-Hexahydro-1-[(*tert*-butyldimethylsilyloxy)-7*a*-methyl-1*H*-indene (9*b*). A solution of 9*a* (2.3 g, 15.13 mmol), imidazole (2.04 g, 30 mmol), and TBSCl (3.3 g, 22 mmol) in dry CH₂Cl₂ (20 mL) and dry DMF (50 mL) was stirred at rt for 24 h. Ice was added in portions, and the mixture was extracted with Et₂O (4 × 100 mL). The organic layers were dried, filtered, and concentrated to give 4 g of 9*b* as a colorless oil (100%; *R*_f 0.63, hexanes): IR (film) 1110 cm⁻¹; ¹H NMR δ 5.33

(1 H, m, H-4), 3.55 (1 H, dd, *J* = 9.7 and 8.0 Hz, H-1), 0.91 (3 H, s, Me-7*a*), 0.89 (9 H, s, *t*-Bu), 0.025 and 0.022 (6 H, 2 s, Me₂Si); ¹³C NMR δ 144.7, 118.9, 82.0, 43.3, 34.9, 29.8, 26.0, 25.8, 25.2, 18.8, 18.0, 17.1, -4.52, -4.87.

[1*S*-(1*α*,3*α*,4*α*,7*α*)]-Octahydro-1-[(*tert*-butyldimethylsilyloxy)-7*a*-methyl-1*H*-indene-4-ol (10). A solution of diborane in dry THF (45 mL, 45 mmol) was added dropwise to an ice-water-cooled solution of 9*b* (4 g, 15 mmol) in dry THF (50 mL). The mixture was stirred at rt for 6 h. The solution was cooled to 0 °C and successively treated dropwise with solutions of NaOH (10%, 20 mL) and H₂O₂ (30%, 50 mL). This mixture was heated to 60 °C for 1 h. THF was removed in vacuo, and H₂O (30 mL) was added. The mixture was extracted with EtOAc (3 × 40 mL). The combined organic phases were dried, filtered, and concentrated to give 4.1 g of a viscous liquid which was flash chromatographed (3 × 40 cm, hexanes-20% Et₂O/hexanes) to afford 3.9 g of 10 (90%; mp 79–81 °C; *R*_f 0.37, 30% Et₂O/hexanes): IR (KBr) 3300, 1100 cm⁻¹; ¹H NMR δ 3.92 (1 H, t, *J* = 7.4 Hz, H-1), 3.32 (1 H, m, H-4), 0.91 (3 H, s, Me-7*a*), 0.87 (9 H, s, *t*-BuSi), 0.004 (6 H, s, Me₂Si); ¹³C NMR δ 75.3, 72.2, 51.9, 45.8, 33.9, 32.0, 30.5, 25.7, 23.9, 22.4, 19.4, 17.9, -4.5, -5.1; MS *m/z* 227 (M⁺ - *t*-Bu, 9), 209 (M⁺ - H₂O, *t*-Bu, 93), 135 (29), 93 (35), 75 (100); high-resolution MS calcd for C₁₂H₂₃O₂Si (C₁₆H₃₂O₂Si - *t*-Bu) 227.1467, found 227.1461. Anal. Calcd for C₁₆H₃₂O₂Si: C, 67.53; H, 11.30. Found: C, 67.12; H, 11.30.

[1*S*-(1*α*,3*α*,7*α*)]-Octahydro-1-[(*tert*-butyldimethylsilyloxy)-7*a*-methyl-4*H*-indene-4-one (11). PDC (10 g, 27 mmol) was added to an ice-water-cooled solution of alcohol 10 (3.8 g, 13.4 mmol) in dry CH₂Cl₂ (150 mL). The mixture was stirred at rt for 10 h, filtered through Celite, and concentrated. The residue was dissolved with EtOAc (100 mL), and the solution was washed with saturated NaHCO₃ (2 × 50 mL). The organic phase was dried, filtered, and concentrated to give 4 g of a brownish viscous oil, which was flash chromatographed (3 × 35 cm, 5% Et₂O/hexanes) to afford a colorless liquid. Bulb-to-bulb distillation gave 3.7 g of 11 (97%, at 120 °C/0.4 mmHg; *R*_f 0.64, 20% Et₂O/hexanes): IR (film) 1710 cm⁻¹; ¹H NMR δ 3.73 (1 H, t, *J* = 6.0 Hz, H-1), 1.04 (3 H, s, Me-7*a*), 0.89 (9 H, s, *t*-BuSi), 0.031 (6 H, s, Me₂Si); ¹³C NMR δ 213.6, 56.6, 50.3, 39.3, 31.8, 31.0, 25.7, 21.9, 21.7, 21.0, 19.2, 17.9, -4.6, -5.1; MS *m/z* 267 (M⁺ - Me, 2), 225 (M⁺ - *t*-Bu, 100), 149 (8.5), 133 (38), 91 (13), 75 (99); high-resolution MS calcd for C₁₂H₂₁O₂Si (C₁₆H₃₀O₂Si - *t*-Bu) 225.1311, found 225.1314. Anal. Calcd for C₁₆H₃₀O₂Si: C, 68.01; H, 10.72. Found: C, 67.62; H, 10.76.

[1*S*-(1*α*,7*α*)]-2,3,5,6,7,7*a*-Hexahydro-1-[(*tert*-butyldimethylsilyloxy)-7*a*-methyl-4-[(trimethylsilyloxy)-1*H*-indene (12). Dry LiH (2 g, 14.85 mmol) and TMSCl (1.42 g, 13.1 mmol, freshly distilled from CaH₂ under N₂) were successively added to a cooled solution (-5 °C) of 11 (3.7 g, 13.1 mmol) and HMDS (2.09 mL, 16.9 mmol, freshly distilled from CaH₂ under N₂) in dry CH₂Cl₂ (80 mL). The mixture was stirred at -5 °C for 3 h and then transferred to a separatory funnel containing ice. The organic phase was washed with an aqueous saturated solution of NaHCO₃ (2 × 30 mL), dried, filtered, and concentrated. The resulting yellowish liquid (12, 4.6 g, 100%) was used in the next experiment without further purification: ¹H NMR δ 3.48 (1 H, m, H-1), 0.88 (12 H, s, (*t*-BuSi and Me-7*a*), 0.15 (15 H, 2 s, Me₂Si and Me₃Si); MS *m/z* 281 (M⁺ - 45, 4), 257 (10), 239 (18), 197 (33), 165 (61), 137 (28), 95 (29), 75 (100).

[1*S*-(1*α*,7*α*)]-1,2,5,6,7,7*a*-Hexahydro-1-[(*tert*-butyldimethylsilyloxy)-7*a*-methyl-4-[(trimethylsilyloxy)-4*H*-indene-4-one (14). A solution of PhSeCl (2.6 g, 13.8 mmol) in dry Et₂O (30 mL) was slowly added via syringe to dry ice-acetone-cooled solution of 12 (4.6 g, 13.1 mmol) in dry Et₂O (40 mL). After 45 min of stirring, an aqueous saturated solution of NaHCO₃ (30 mL) was added. The organic layer was washed with saturated NaHCO₃ (2 × 15 mL), dried, filtered, and concentrated to give 5.3 g of a yellowish solid which was flash chromatographed (3 × 40 cm, hexanes) to afford 5.1 g of phenylselenyl ketones 13: ¹H NMR δ 7.47–7.24 (5 H, m, Ph), 3.80 (1 H, t, *J* = 8.6 Hz, H-1), 1.19 and 0.87 (3 H, 2s, Me-7*a*), 0.89 (9 H, s, *t*-Bu), 0.01 (6 H, Me₂Si). The mixture was dissolved in dry CH₂Cl₂ (200 mL), and the solution was cooled to -78 °C. Pure *m*-CPBA (4.5 g, 26 mmol) was added, and the reaction mixture was stirred at this temperature for 30 min. A few drops of a saturated solution of NaHCO₃ were added, and the mixture was washed with a satu-

rated solution of NaHCO_3 (2 × 30 mL) and water (30 mL). The organic phase was dried, filtered, and concentrated to give a yellowish liquid which was flash chromatographed (3 × 30 cm, 5% Et_2O /hexanes) to afford 2.6 g of 14 (70%): IR (film) 1690 cm^{-1} ; UV (EtOH) λ_{max} 252.3 nm ($\epsilon = 11000$); ^1H NMR δ 6.4 (1 H, m, H-3), 4.08 (1 H, m, H-1), 0.97 (3 H, s, Me-7a), 0.87 (9 H, s, *t*-Bu), 0.03 (6 H, s, Me_2Si). Anal. Calcd for $\text{C}_{16}\text{H}_{26}\text{O}_2\text{Si}$: C, 68.49; H, 10.00. Found: C, 68.06; H, 10.24.

[1S-(1 α ,4 β ,7 α)]-2,4,5,6,7,7a-Hexahydro-1-[(*tert*-butyldimethylsilyloxy)-7a-methyl-1H-inden-4-ol (15a). NaBH_4 (1.2 g, 31.5 mmol) was added to an ice-water-cooled solution of 14 (2.8 g, 10 mmol) and $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (2 g, 5.4 mmol) in MeOH (50 mL). After 15 min of stirring, the reaction was quenched by addition of drops of water. The mixture was concentrated and the residue dissolved in EtOAc (100 mL). The organic phase was washed with H_2O (3 × 50 mL), dried, filtered, and concentrated to give a residue which was flash chromatographed (2 × 30 cm, 10% EtOAc/hexanes). Bulb-to-bulb distillation afforded 2.6 g of 15a (92%; at 120–130 °C/1 mmHg, colorless liquid): ^1H NMR δ 5.35 (1 H, m, H-3), 4.17 (1 H, m, H-4), 3.99 (1 H, t, $J = 8.0$ Hz, H-1), 0.94 (3 H, s, Me-7a), 0.89 (9 H, s, *t*-Bu), 0.04 (6 H, s, Me_2Si); MS m/z 267 ($\text{M}^+ - \text{Me}$, 2), 264 ($\text{M}^+ - \text{H}_2\text{O}$, 10), 225 ($\text{M}^+ - \text{t-Bu}$, 33), 149 (15), 133 (36), 75 (100); high-resolution MS calcd for $\text{C}_{12}\text{H}_{21}\text{O}_2\text{Si}$ ($\text{C}_{16}\text{H}_{30}\text{O}_2\text{Si} - \text{t-Bu}$) 225.1311, found 225.1298. Anal. Calcd for $\text{C}_{16}\text{H}_{30}\text{O}_2\text{Si}$: C, 68.01; H, 10.72. Found: C, 67.89; H, 10.48.

[1S-(1 α ,3 α ,4 β ,7 α)]-Octahydro-1-[(*tert*-butyldimethylsilyloxy)-7a-methyl-1H-inden-4-ol (16). Hydrogenation of 15a in the Presence of Crabtree's Catalyst. Crabtree's catalyst, $[\text{Ir}(\text{Cod})\text{Py}(\text{PCy}_3)]\text{PF}_6$ (30 mg, 0.04 mmol), was added to a degassed and cooled (−78 °C) solution of 15a (50 mg, 0.2 mmol) in dry CH_2Cl_2 (25 mL). The mixture was degassed, and H_2 was introduced at a pressure of 40 psi. After 30 h of stirring, the mixture was concentrated and the residue was flash chromatographed (2 × 15 cm, 10% EtOAc/hexanes) to afford 46 mg of 16 (92%; R_f 0.6, 30% EtOAc/hexanes): ^1H NMR δ 3.88 (1 H, m, H-4), 3.66 (1 H, dd, $J = 5.5$ and 1.0 Hz, H-1), 0.98 (3 H, s, Me-7a), 0.88 (9 H, s, *t*-Bu), 0.02 and 0.01 (6 H, 2 s, Me_2Si); ^{13}C NMR δ 82.0, 69.6, 47.6, 47.5, 32.1, 30.7, 29.5, 25.7, 21.3, 20.4, 19.4, 18.0, −4.7, −5.0; MS m/z 284 (M^+ , 0.9), 227 ($\text{M}^+ - \text{t-Bu}$, 18), 209 ($\text{M}^+ - \text{H}_2\text{O}$, *t*-Bu, 100), 151 (16), 133 (31), 107 (22), 93 (34), 75 (67). Anal. Calcd for $\text{C}_{16}\text{H}_{32}\text{O}_2\text{Si}$: C, 67.53; H, 11.36. Found: C, 67.22; H, 11.48.

[1S-(1 α ,3 α ,4 β ,7 α)]-Octahydro-1-[(*tert*-butyldimethylsilyloxy)-7a-methyl-1H-inden-4-ol (4). Hydrogenation of 15a in the Presence of Wilkinson's Catalyst. A degassed solution of Wilkinson's catalyst (200 mg, 0.22 mmol) in dry benzene (50 mL) was hydrogenated (40 psi) with stirring for 1 h, and then a solution of the alcohol 15a (250 mg, 0.89 mmol) in dry benzene (50 mL) was added. The mixture was hydrogenated at the same pressure for 24 h with stirring. After concentration, the residue was flash chromatographed (2 × 20 cm, 10% EtOAc/hexanes) to give 162 mg of 4 as a colorless solid (65%; mp 72–3 °C; R_f 0.5, 30% EtOAc/hexanes) and 55 mg of 16 (22%): ^1H NMR δ 3.60 (2 H, m, H-1 and H-4), 0.87 (9 H, s, *t*-Bu), 0.70 (3 H, s, Me-7a), 0.004 (6 H, s, Me_2Si); ^{13}C NMR δ 81.6, 71.2, 51.6, 45.3, 36.3, 36.1, 30.4, 25.7, 22.7, 21.5, 18.0, 11.1, −4.6, −4.9; MS m/z 284 (M^+ , 0.5), 227 ($\text{M}^+ - \text{t-Bu}$, 65), 209 ($\text{M}^+ - \text{H}_2\text{O}$, *t*-Bu, 23), 151 (39), 135 (43), 93 (28), 75 (100). Anal. Calcd for $\text{C}_{16}\text{H}_{32}\text{O}_2\text{Si}$: C, 67.53; H, 11.36. Found: C, 67.59; H, 11.34.

[1R-(1 α (*S**),3 α β ,4 α ,7 α)]-Octahydro-4-[(*tert*-butyldimethylsilyloxy)- β ,7a-dimethyl-1H-indene-1-ethanol *p*-Toluenesulfonate (18b). Imidazole (0.17 g, 2.5 mmol) and TBSCl (200 mg, 1.32 mmol) were successively added to a solution of 18a^{8f,21} (300 mg, 0.82 mmol) in dry CH_2Cl_2 (3 mL) and DMF (8 mL). The solution was stirred at rt for 24 h and at 55 °C for 30 h and then quenched by the addition of ice. The mixture was extracted with Et_2O (3 × 20 mL) and washed with an aqueous solution of HCl (10%, 20 mL) and brine (20 mL). The combined organic phases were dried, filtered, and concentrated to give a residue which was flash chromatographed (hexanes) to afford 334 mg of 18b (85%; R_f 0.7, 8% EtOAc/hexanes; mp 50 °C (lit.²² mp 50 °C), white solid): ^1H NMR δ 7.79 (2 H, d, $J = 8.35$ Hz, Ar), 7.35 (2 H, d, $J = 8.4$ Hz, Ar), 3.98 (1 H, m, H-4), 3.95 (1 H, dd, $J = 9.2$ and 3.1 Hz, H- α), 3.8 (1 H, dd, $J = 9.2$ and 6.3 Hz, H- α), 2.46 (3 H, s, MeAr), 0.95 (3 H, d, $J = 6.7$ Hz, Me- β), 0.88 (9 H,

s, *t*-BuSi), 0.87 (3 H, s, Me-7a), 0.005 (6 H, s, Me_2Si).

[1R-(1 α (*S**),3 α β ,4 α ,7 α)]-Octahydro-4-[(*tert*-butyldimethylsilyloxy)- β ,7a-dimethyl-1H-indene-1-acetaldehyde (19). A solution of tosylate 18b (150 mg, 0.31 mmol) and dry NaHCO_3 (26 mg, 0.31 mmol) in dry DMSO (5 mL, previously heated at 150 °C for 5 min and allowed to reach rt under argon) was heated at 120 °C for 2 h. The mixture was cooled to rt, and solutions of brine (10 mL) and Et_2O (10 mL) were successively added. The organic phase was washed with H_2O (2 × 10 mL). The combined aqueous phases were extracted with Et_2O (2 × 10 mL). The combined organic phases were dried, filtered, and concentrated. The residue was flash chromatographed (1 × 16 cm, 1% EtOAc/hexanes) to afford 85 mg of aldehyde 19²⁴ (85%; R_f 0.48, 15% EtOAc/hexanes): IR (film) 1710 cm^{-1} ; ^1H NMR δ 9.58 (1 H, d, $J = 3.2$ Hz, H- α), 4.04 (1 H, m, H-4), 2.36 (1 H, m, H- β), 1.08 (3 H, d, $J = 7.0$ Hz, Me- β), 0.95 (3 H, s, Me-7a), 0.88 (9 H, s, *t*-BuSi), 0.01 (6 H, 2 s, Me_2Si); ^{13}C NMR δ 205.2, 69.1, 52.4, 51.7, 49.1, 42.6, 40.4, 34.3, 30.3, 26.2, 25.8, 23.3, 17.5, 14.0, 13.3, −4.9, −5.2.

[1S-(1 α ,3 α β ,4 α ,7 α)]-Octahydro-1-acetyl-4-[(*tert*-butyldimethylsilyloxy)-7a-methyl-1H-indene (20). O_2 was bubbled through a solution of KO-*t*-Bu (1.8 g, 16 mmol) in dry *t*-BuOH (35 mL, freshly distilled from CaH_2), at rt, for 10 min, and then a solution of aldehyde 19 (1.06 g, 3.27 mmol) in *t*-BuOH (20 mL) was added. O_2 was bubbled through the suspension for 10 min followed by N_2 for 15 min. Water (25 mL) was added, and the mixture was extracted with Et_2O (3 × 50 mL). The combined organic phases were dried, filtered, and concentrated. The residue was flash chromatographed (2.5 × 19 cm, 1–2% EtOAc/hexanes) to afford 818 mg of 20 (82%; R_f 0.41, 15% EtOAc/hexanes; mp 34–5 °C, white solid); IR (film) 1700 cm^{-1} ; ^1H NMR δ 4.04 (1 H, m, H-4), 2.47 (1 H, t, $J = 8.7$ Hz, H-1), 2.09 (3 H, s, MeCO), 0.87 (9 H, s, *t*-BuSi), 0.85 (3 H, s, Me-7a), 0.01 and 0.005 (6 H, s, Me_2Si); ^{13}C NMR δ 209.5, 69.0, 64.5, 53.2, 43.7, 39.8, 34.2, 30.8, 25.7, 23.2, 21.8, 17.6, 15.4, −4.9, −5.3; MS m/z 267 ($\text{M}^+ - 43$, 5), 253 ($\text{M}^+ - \text{t-Bu}$, 69), 225 (19), 179 (10), 161 (17), 145 (25), 119 (46), 75 (100); high-resolution MS calcd for $\text{C}_{14}\text{H}_{25}\text{O}_2\text{Si}$ ($\text{C}_{18}\text{H}_{34}\text{O}_2\text{Si} - \text{t-Bu}$) 253.1624, found 253.1642.

[1S-(1 α ,3 α β ,4 α ,7 α)]-Octahydro-1-(acetyloxy)-4-[(*tert*-butyldimethylsilyloxy)-7a-methyl-1H-indene (21a). Pure *m*-CPBA (130 mg, 0.75 mmol) was added to an ice-cooled solution of ketone 20 (110 mg, 0.36 mmol) in dry CH_2Cl_2 (3 mL). The mixture was stirred at rt for 7 days [additional amounts of *m*-CPBA were successively added (60 mg, 24 h; 50 mg, 78 h; 30 mg, 98 h; 55 mg, 120 h)]. An aqueous saturated solution of NaHCO_3 (10 mL) and CH_2Cl_2 (10 mL) were added, and the aqueous phase was extracted with CH_2Cl_2 (2 × 10 mL). The combined organic phases were dried, filtered, and concentrated to afford, after flash chromatography (1.5 × 16 cm, 1% EtOAc/hexanes), 81 mg of 21a (70%, white solid; mp 47–9 °C): ^1H NMR δ 4.54 (1 H, dd, $J = 9.0$ and 7.7 Hz, H-1), 4.01 (1 H, m, H-4), 2.03 (3 H, s, MeCO₂), 1.01 (3 H, s, Me-7a), 0.89 (9 H, s, *t*-BuSi), 0.017 and 0.003 (6 H, 2 s, Me_2Si); ^{13}C NMR δ 171.3, 82.9, 69.1, 47.8, 25.8, 22.2, 21.1, 18.0, 17.1, 13.7, −4.9, −5.2; MS m/z 326 (M^+ , 17), 283 ($\text{M}^+ - \text{Ac}$, 12), 281 ($\text{M}^+ - 45$, 38), 269 ($\text{M}^+ - \text{t-Bu}$, 25), 135 (100), 105 (44), 91 (37), 75 (45). Anal. Calcd for $\text{C}_{18}\text{H}_{34}\text{O}_3\text{Si}$: C, 66.21; H, 10.49. Found: C, 66.07; H, 10.77.

[1S-(1 α ,3 α β ,4 α ,7 α)]-Octahydro-4-[(*tert*-butyldimethylsilyloxy)-7a-methyl-1H-inden-1-ol (21b). A solution of acetate 21a (70 mg, 0.22 mmol) in MeOH (2 mL) and H_2O (0.1 mL) was cooled in an ice-water bath and treated with NaOH (200 mg, 5 mmol). The resulting mixture was stirred at rt overnight and then washed with an aqueous saturated solution of NH_4Cl and extracted with Et_2O (4 × 15 mL). The combined organic phases were dried, filtered, and concentrated to give a white solid which was flash chromatographed (1 × 15 cm, 5% EtOAc/hexanes) to afford 56 mg of 21b (92%; R_f 0.27, 15% EtOAc/hexanes; mp 69–71 °C, white solid): ^1H NMR δ 4.01 (1 H, m, H-4), 3.57 (1 H, t, $J = 8.3$ Hz, H-1), 2.04 (1 H, m, H-3a), 0.97 (3 H, s, Me-7a), 0.90 (9 H, s, *t*-BuSi), 0.023 and 0.007 (6 H, 2 s, Me_2Si); ^{13}C NMR δ 82.2, 69.2, 48.1, 42.1, 37.4, 34.4, 29.9, 25.8, 22.3, 18.0, 17.2, 12.5, −4.9, −5.2; MS m/z 284 (M^+ , 7), 227 ($\text{M}^+ - \text{t-Bu}$, 53), 209 ($\text{M}^+ - \text{t-Bu} - \text{H}_2\text{O}$, 100), 191 (10), 133 (24), 107 (27), 93 (33), 75 (45); high-resolution MS calcd for $\text{C}_{16}\text{H}_{32}\text{O}_2\text{Si}$ 284.2171, found 284.2147.

[3 α R-(3 α β ,4 α ,7 α)]-Octahydro-4-[(*tert*-butyldimethylsilyloxy)-7a-methyl-1H-inden-1-one (6). PDC (85 mg, 0.23

mmol) was added to a solution of alcohol 21b (42 mg, 0.15 mmol) in dry CH_2Cl_2 (8 mL). The resulting suspension was stirred at rt overnight and then filtered through a Celite path. The solution was concentrated to give a residue which was flash chromatographed (1 × 14 cm, 3% EtOAc/hexanes) to afford 38 mg of ketone 6 (91%) which shows ^1H NMR and ^{13}C NMR identical to those of the compound obtained above.

Preparation of [1S-(1 α ,3 α , β ,4 α ,7 α)]-Octahydro-1,4-dihydroxy-7 α -methyl-1H-indene (22) from 4 through 17 and 23. [1S-(1 α ,3 α , β ,7 α)]-Octahydro-1-[(*tert*-butyldimethylsilyloxy)-7 α -methyl-4H-inden-4-one (17)]. PDC (140 mg, 0.53 mmol) was added to an ice-water-cooled solution of alcohol 4 (100 mg, 0.35 mmol) in dry CH_2Cl_2 (20 mL). The resulting suspension was stirred at rt for 4 h, filtered through Celite, and concentrated to give a residue which was dissolved with EtOAc (100 mL). This solution was washed with an aqueous saturated solution of NaCHO_3 (2 × 50 mL), dried, filtered, and concentrated to give a brown viscous liquid which was flash chromatographed (5% Et₂O/hexanes) to afford 98 mg of 17 (98%; R_f 0.55, 15% EtOAc/hexanes; colorless liquid): IR (film) 1710 cm^{-1} ; ^1H NMR δ 3.84 (1 H, t, J = 8.5 Hz, H-3a), 0.88 (9 H, s, *t*-BuSi), 0.67 (3 H, s, Me-7a), 0.04 and 0.03 (6 H, 2 s, Me₂Si). Anal. Calcd for $\text{C}_{16}\text{H}_{30}\text{O}_2\text{Si}$: C, 68.01; H, 10.72. Found: C, 67.86; H, 10.53.

[1S-(1 α ,3 α , β ,4 α ,7 α)]-Octahydro-1-[(*tert*-butyldimethylsilyloxy)-7 α -methyl-1H-inden-4-ol (23)]. (23). NaBH_4 (30 mg, 0.79 mmol) was added to an ice-water-cooled solution of 17 (109 mg, 0.39 mmol, prepared from 4 as above) in absolute EtOH (4 mL). The resulting mixture was stirred for 1 h at rt, and then H_2O (5 mL) was added. The mixture was concentrated to a small volume, and the residue was extracted with Et₂O (2 × 5 mL). The combined organic phases were dried, filtered, and concentrated to give a residue which was flash chromatographed (1 × 15 cm, 5% EtOAc/hexanes) to afford 94 mg of 23 (84%; R_f 0.7, 30% EtOAc/hexanes; colorless oil) and 18 mg of 4 (15%; R_f 0.6, 30% EtOAc/hexanes; white solid): ^1H NMR δ 4.03 (1 H, m H-4), 3.52 (1 H, t, J = 7.8 Hz, H-1), 0.95 (3 H, m, Me-7a), 0.88 (9H, s, *t*-Bu), 0.01 (3 H, s, Me₂Si); ^{13}C NMR δ 81.8, 69.3, 47.3, 42.2, 37.5, 33.8, 29.9, 25.8, 21.8, 18.0, 17.1, 12.6, -4.6, -5.0.

[1S-(1 α ,3 α , β ,4 α ,7 α)]-Octahydro-1,4-dihydroxy-7 α -methyl-1H-indene (22). An aqueous solution of HF (48%, 17 drops) was added to a solution of 23 (91 mg, 0.32 mmol) in CH_3CN (5 mL). The resulting solution was stirred overnight at rt. After concentration, an aqueous saturated solution of NaHCO_3 (15 mL)

was added and the mixture was extracted with Et₂O (4 × 10 mL). The combined organic phases were dried, filtered, and concentrated. The residue was flash chromatographed (1 × 10 cm, 20% EtOAc/hexanes) to give 44 mg of 22 (81%; R_f 0.15, 30% EtOAc/hexanes; white solid; mp 135–7 °C): ^1H NMR δ 4.08 (1 H, m, H-4), 3.61 (1 H, t, J = 8.5 Hz, H-1), 1.00 (3 H, s, Me-7a); ^{13}C NMR δ 81.9, 69.0, 47.6, 41.9, 37.1, 33.7, 29.6, 21.7, 17.0, 12.2.

Alternative Route for Preparation of 22 from 6 through 21b. NaBH_4 (20 mg, 0.53 mmol) was added to an ice-water-cooled solution of 6 (43 mg, 0.15 mmol) in absolute EtOH (3 mL). The resulting mixture was stirred for 1 h at rt, and then H_2O (5 mL) was added. The mixture was concentrated to a small volume. The residue was extracted with Et₂O (2 × 5 mL), and the combined organic phases were dried, filtered, and concentrated to give 42 mg of 21b (97%; R_f 0.3, 15% EtOAc/hexanes; white solid), which shows ^1H NMR and ^{13}C NMR identical to those of the compound obtained above. An aqueous solution of HF (48%, five drops) was added to a solution of 21b (34 mg, 0.12 mmol) in CH_3CN (2 mL). The solution was stirred for 20 h. After concentration, an aqueous saturated solution of NaHCO_3 (10 mL) was added and the mixture was extracted with Et₂O (4 × 10 mL). The combined organic phases were dried, filtered, and concentrated, and the resulting residue was flash chromatographed (1 × 10 cm, 20% EtOAc/hexanes) to give 16 mg of 22 (80%; R_f 0.15, 30% EtOAc/hexanes; white solid, mp 134–6 °C). The ^1H NMR and ^{13}C NMR spectra were identical to those of the compound obtained from 23 as above.

Acknowledgment. We thank the Spanish Ministry of Education and Science for financial support (DGICYT Project no. PB87-0478). We also thank Duphar for the generous gift of vitamin D₂ used for the preparation of Lythgoe-Inhoffen diol (3). We thank J. Sestelo for the preparation of aldehyde 19 via the modified Kornblum's method, G. Tojo for the high-resolution MS, and Prof. J. M. Aizpurua (Universidad del Pais Vasco) for some elemental analyses.

Supplementary Material Available: ^1H NMR spectra of 4, 6, 7a, 7b, 8, 9a, 9b, 10–14, 15a, 16, 17, 18b, 19, 20, 21a, 21b, 22, and 23 and ^{13}C NMR spectra of 4, 6, 9a, 9b, 10, 11, 16, 19, 20, 21a, 21b, 22, and 23 (35 pages). Ordering information is given on any current masthead page.

Transmetalation Reactions of Alkenylalanes: Copper-Catalyzed Conjugate Addition to Enones

Peter Wipf,* Jacqueline H. Smitrovich, and Choong-Woon Moon

Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260

Received January 22, 1992

An improved synthetic strategy for the in situ preparation of vinyl cuprates from alkynes is presented and used for the stereospecific synthesis of di-, tri-, and tetrasubstituted olefins. Hydroalumination or Cp_2ZrCl_2 -catalyzed carboalumination of alkynes, followed by in situ transmetalation to bis-alkynyl-copper complex $[(\text{C}_4\text{H}_9\text{C}\equiv\text{C})_2\text{CuCN}]\text{Li}_2$ and addition of enones, led to the isolation of 1,4-addition products in high yields. Stoichiometric or catalytic amounts of copper complex gave similar results. However, in the presence of less than 10 mol % of Cu(I) complex, side products were formed and a significant drop in the yield of the desired conjugate addition product was observed. An ate-transfer mechanism is postulated for the rapid exchange of vinyl ligands from Al(III) to Cu(I) at low temperatures.

Introduction

The development of the chemistry of organocuprates has resulted in many important applications in organic synthesis, such as conjugate additions to α,β -unsaturated carbonyl compounds,¹ nucleophilic displacements on

halides,² sulfonates,³ and allylic acetates,^{4,5} epoxide ring openings,⁶ and additions to acetylenes.⁷ However, the vast

- (2) (a) Corey, E. J.; Posner, G. H. *J. Am. Chem. Soc.* 1967, 89, 3911.
 (b) Marfat, A.; McGuirk, P. R.; Helquist, P. *J. Org. Chem.* 1979, 44, 3888.
 (c) Normant, J. F.; Alexakis, A. *Synthesis* 1981, 841.
 (3) Johnson, C. R.; Dutra, G. A. *J. Am. Chem. Soc.* 1973, 95, 7783.
 (4) Anderson, R. J.; Henrick, C. A.; Siddall, J. B.; Zurfluh, R. *J. Am. Chem. Soc.* 1972, 94, 5379.

(1) House, H. O.; Respass, W. L.; Whitesides, G. M. *J. Org. Chem.* 1966, 31, 3128.